Frontlight ResearchEarly access
Liver and biliary tract cancer trials in China
616 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- No phaseEnrolling by invitationThe Effects of a Nurse-led TGA-based Pre-rehabilitation Planning on Perioperative Outcomes in Patients With Liver Cancer: Study and Protocol
- Where
- Shanghai
- Age
- 18 years to 84 years
- People
- 92
- Run by
- Fudan University
See details and how to joinNCT07537205 - Phase 2Not yet taking people in ChinaBenmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 29
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT07537777 - Phase 3Not yet taking people in ChinaLocal Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 400
- Run by
- Tongji Hospital
See details and how to joinNCT07537946 - No phaseNot yet taking people in ChinaSurgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 280
- Run by
- Tongji Hospital
See details and how to joinNCT07537959 - Phase 2Not yet taking people in ChinaDenosumab Strategy for Liver Cancer With Bone Metastases
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 50
- Run by
- Tongji Hospital
See details and how to joinNCT07537972 - Phase 1/2Taking peopleHX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
- Where
- Beijing
- Age
- 18 years to 70 years
- People
- 124
- Run by
- Hangzhou Hanx Biopharmaceuticals, Ltd.
See details and how to joinNCT06708663 - Phase 2/3Taking peopleA Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
- Where
- Hefei, Shanghai
- Age
- 18 years to 75 years
- People
- 680
- Run by
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
See details and how to joinNCT07490262 - Phase 2Taking peoplePhase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
- Where
- Guangzhou
- Age
- 18 years to 70 years
- People
- 40
- Run by
- Sun Yat-sen University
See details and how to joinNCT07530445 - Phase 3Taking peopleTACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
- Where
- Chengdu
- Age
- 18 years to 80 years
- People
- 101
- Run by
- Guohui Xu
See details and how to joinNCT06485466 - No phaseTaking peopleSingle-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease
- Where
- Guangzhou
- People
- 240
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT07265544 - No phaseTaking peopleElectronic Symptom Monitoring of Patient-Reported Outcomes Among Patients With Hepatocellular Carcinoma During Immunotherapy (PRIME-HCC): Protocol for a Randomised Controlled Trial
- Where
- Haidian
- Age
- 18 years to 75 years
- People
- 500
- Run by
- Wei Xiaoping
See details and how to joinNCT06938945 - Phase 1/2Taking peopleBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
- Where
- Shenzhen
- Age
- 18 years to 75 years
- People
- 72
- Run by
- Beijing Biotech
See details and how to joinNCT07523529 - Phase 1/2Taking peopleA Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
- Where
- Anyang, Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Fuyang, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jiangmen, Jiaxing, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Tangshan, Tianjin, Wuhan, Xi’an, Yancheng, Yichang, Zhengzhou
- Age
- 18 years to 75 years
- People
- 102
- Run by
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
See details and how to joinNCT06431490 - Phase 1Taking peopleA Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
- Where
- Beijing, Bengbu, Changsha, Chongqing, Fuzhou, Guangzhou, Haerbin, Jinan, Linyi, Luoyang, Mianyang, Nanning, Ningbo, Shenyang, Suzhou, Tonghua, Weifang, Wuhan, Xian, Yinchuan, Zhengzhou
- Age
- 18 years to 75 years
- People
- 200 worldwide
- Run by
- Abbisko Therapeutics Co, Ltd
See details and how to joinNCT04906434 - Phase 2Taking peopleTrastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy
- Where
- Shenyang
- Age
- 18 years to 85 years
- People
- 20
- Run by
- Xiujuan Qu
See details and how to joinNCT07506057 - Phase 2Taking peopleA Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
- Where
- Beijing, Shanghai
- Age
- 18 years to 75 years
- People
- 151
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07450976 - No phaseTaking peopleLarge Language Models Assist in Tumor MDT
- Where
- Guangzhou
- Age
- 25 years to 33 years
- People
- 60
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07504367 - Phase 1/2Taking peopleDual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
- Where
- Shenzhen
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Beijing Biotech
See details and how to joinNCT07500220 - Phase 2Taking peopleEfficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 80
- Run by
- Sun Yat-sen University
See details and how to joinNCT07501351 - Phase 2Taking peopleSintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
- Where
- Changchun, Sanming, Shanghai
- Age
- 18 years to 75 years
- People
- 35
- Run by
- Ruijin Hospital
See details and how to joinNCT07331883 - Phase 2Not yet taking people in ChinaPhase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 230
- Run by
- Zhejiang Haichang Biotech Co., Ltd.
See details and how to joinNCT07494435 - Phase 1/2Taking peopleA Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 20
- Run by
- Yinghua Xu
See details and how to joinNCT07495215 - Phase 1/2Taking peoplePhase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Where
- Beijing, Bengbu, Changchun, Dalian, Dongguan, Fuzhou, Guangzhou, Haerbin, Hangzhou, Jinan, Kunming, Nanchang, Shanghai, Shenyang, Taiyuan, Tianjin, Ürümqi, Xiamen, Zhengzhou, Zhuhai
- Age
- 18 years and over
- People
- 170
- Run by
- 3D Medicines (Sichuan) Co., Ltd.
See details and how to joinNCT05024214 - Phase 1/2Taking peopleAdebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
- Where
- Wuhan
- Age
- 18 years and over
- People
- 29
- Run by
- Tongji Hospital
See details and how to joinNCT07392541 - No phaseTaking peoplecfDNA Methylation for Liver Cancer Recurrence Detection
- Where
- Wuhan
- Age
- 18 years and over
- People
- 500
- Run by
- Wuhan Ammunition Life-tech Co., Ltd
See details and how to joinNCT07466602